Lefunomide en es it fr

Lefunomide Brand names, Lefunomide Analogs

Lefunomide Brand Names Mixture

  • No information avaliable

Lefunomide Chemical_Formula


Lefunomide RX_link


Lefunomide fda sheet

Lefunomide FDA

Lefunomide msds (material safety sheet)

Lefunomide MSDS

Lefunomide Synthesis Reference

No information avaliable

Lefunomide Molecular Weight

270.207 g/mol

Lefunomide Melting Point

165-166 oC

Lefunomide H2O Solubility

21 mg/L (poorly soluble)

Lefunomide State


Lefunomide LogP


Lefunomide Dosage Forms


Lefunomide Indication

For the treatment of active rheumatoid arthritis (RA).

Lefunomide Pharmacology

Leflunomide is a pyrimidine synthesis inhibitor indicated in adults for the treatment of active rheumatoid arthritis (RA). RA is an auto-immune disease characterized by high T-cell activity. T cells have two pathways to synthesize pyrimidines: the salvage pathways and the de novo synthesis. At rest, T lymphocytes meet their metabolic requirements by the salvage pathway. Activated lymphocytes need to expand their pyrimidine pool 7- to 8-fold, while the purine pool is expanded only 2- to 3-fold. To meet the need for more pyrimidines, activated T cells use the de novo pathway for pyrimidine synthesis. Therefore, activated T cells, which are dependent on de novo pyrimidine synthesis, will be more affected by leflunomide's inhibition of dihydroorotate dehydrogenase than other cell types that use the salvage pathway of pyrimidine synthesis.

Lefunomide Absorption

Well absorbed, peak plasma concentrations appear 6-12 hours after dosing

Lefunomide side effects and Toxicity

LD50=100-250 mg/kg (acute oral toxicity)

Lefunomide Patient Information

No information avaliable

Lefunomide Organisms Affected

Humans and other mammals